<DOC>
	<DOC>NCT00577148</DOC>
	<brief_summary>The purpose of this study is to assess the effect of rimonabant treatment on the histological features of Nonalcoholic Steatohepatitis (NASH) in patients with Type 2 diabetes.</brief_summary>
	<brief_title>An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes</brief_title>
	<detailed_description>The total duration per patient will be approximately 22 months including a 18-month double-blind treatment period.</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Rimonabant</mesh_term>
	<criteria>Patients with Type 2 diabetes mellitus and a diagnosis of NASH Excessive alcohol use Presence of Type 1 diabetes mellitus Other chronic liver disease Previous or current hepatocellular carcinoma Use of medication known to cause steatosis Previous bariatric surgery Pregnancy or breastfeeding Presence of any severe medical or psychological condition that, in the opinion of the investigator, would compromise the patient's safe participation including uncontrolled serious psychiatric illness such a major depression within the last 2 years, and history of other severe psychiatric disorders The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>NASH</keyword>
	<keyword>chronic liver disease</keyword>
</DOC>